1. Pink Sheet

Post-Brexit UK Could Lose Access To EU’s Drug Safety Database

 
• By Ian Schofield

One of the many ramifications of the UK’s decision to leave the EU is that it could lose access to the revamped EudraVigilance adverse drug reaction database.

Brexit
The UK could lose access to a valuable source of drug safety data as a result of Brexit

The UK is likely to lose its access to the European Medicines Agency’s EudraVigilance database of drug adverse reactions as a result of Brexit, unless some sort of agreement for continued access can be reached, experts have warned.

The draft withdrawal agreement that was published by the EU on Feb. 28 states that at the end of any...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 
• By Eliza Slawther

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 
• By Sarah Karlin-Smith

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.